Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP476413.RAvwp_vhm_Hwf_44Ymqf5wiwtueeeLBZgrzvo45-cX9Do130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP476413.RAvwp_vhm_Hwf_44Ymqf5wiwtueeeLBZgrzvo45-cX9Do130_assertion type Assertion NP476413.RAvwp_vhm_Hwf_44Ymqf5wiwtueeeLBZgrzvo45-cX9Do130_head.
- NP476413.RAvwp_vhm_Hwf_44Ymqf5wiwtueeeLBZgrzvo45-cX9Do130_assertion description "[In conclusion, a 24-month course of treatment with 6 MU IFN-alpha2b was well tolerated by most patients, led to sustained suppression of HBV in one third, and attenuated hepatitis in 81% of patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP476413.RAvwp_vhm_Hwf_44Ymqf5wiwtueeeLBZgrzvo45-cX9Do130_provenance.
- NP476413.RAvwp_vhm_Hwf_44Ymqf5wiwtueeeLBZgrzvo45-cX9Do130_assertion evidence source_evidence_literature NP476413.RAvwp_vhm_Hwf_44Ymqf5wiwtueeeLBZgrzvo45-cX9Do130_provenance.
- NP476413.RAvwp_vhm_Hwf_44Ymqf5wiwtueeeLBZgrzvo45-cX9Do130_assertion SIO_000772 9398007 NP476413.RAvwp_vhm_Hwf_44Ymqf5wiwtueeeLBZgrzvo45-cX9Do130_provenance.
- NP476413.RAvwp_vhm_Hwf_44Ymqf5wiwtueeeLBZgrzvo45-cX9Do130_assertion wasDerivedFrom befree-20150227 NP476413.RAvwp_vhm_Hwf_44Ymqf5wiwtueeeLBZgrzvo45-cX9Do130_provenance.
- NP476413.RAvwp_vhm_Hwf_44Ymqf5wiwtueeeLBZgrzvo45-cX9Do130_assertion wasGeneratedBy ECO_0000203 NP476413.RAvwp_vhm_Hwf_44Ymqf5wiwtueeeLBZgrzvo45-cX9Do130_provenance.